Skip to content
BHP

BPC-157 vs TB-500

BPC-157 and TB-500 are the two most-discussed research peptides in soft-tissue repair. They have overlapping interest areas — tendon, ligament, and vascular healing — but operate by different mechanisms and rest on quite different bodies of evidence.

BPC-157

A 15-amino-acid pentadecapeptide derived from a protective protein found in human gastric juice. The most-studied healing research peptide, with extensive pre-clinical work on tendon, ligament, gut, and vascular repair.

TB-500

A synthetic peptide commonly described as a fragment of thymosin beta-4 incorporating the actin-binding 'LKKTETQ' motif. Studied for soft-tissue repair, wound healing, and cardiac tissue regeneration in animal models.

Mechanism

BPC-157 acts primarily on the nitric-oxide system and growth-hormone-receptor expression in tendon fibroblasts, with documented angiogenic effects via VEGFR2-eNOS signalling. TB-500 (a fragment of thymosin beta-4) is described as an actin-binding peptide that mobilises cellular migration and upregulates laminin-5, MMP-2/-9, and VEGF.

Evidence base

BPC-157 has accumulated over 100 indexed pre-clinical studies, largely from the Sikiric group. TB-500's published literature is smaller; many citations refer to full-length Tβ4 rather than the commercial fragment, an important caveat when interpreting outcomes.

Half-life and route

BPC-157 has a short plasma half-life (<1 hour in rodents) with rapid distribution; commercial TB-500 is generally administered by subcutaneous or intramuscular injection in research protocols.

Anti-doping

Both peptides are prohibited by WADA — BPC-157 under S0 (non-approved substances), TB-500 under S2 (peptide hormones, growth factors, related substances and mimetics).

Stacking considerations

Anecdotal research-community use frequently combines the two on the basis that BPC-157 contributes vascular/anti-inflammatory effects while TB-500 contributes cell-migration effects. Formal pharmacological evidence for additive or synergistic action in controlled studies is limited.

Verdict

For tendon and ligament research, BPC-157 currently has the deeper published evidence base; TB-500 remains of interest particularly for migration-dependent processes such as cardiac and corneal repair, but batch identity and fragment-vs-full-length distinctions matter.

Where to source research peptides for laboratory research

The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.

  • PeptideAuthority.co.uk

    UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.

  • PeptideBarn.co.uk

    Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.